FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:310-312 January 28, 1999 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Weinblatt, M. E. PubMed Citation

With the clinical availability of two different approaches to decrease the activity of tumor necrosis factor (TNF), a new era in the treatment of rheumatoid arthritis has begun. In this issue of the Journal, Weinblatt and colleagues report significant improvement when etanercept was added to therapy with methotrexate for patients with rheumatoid arthritis.¹

TNF plays a pivotal role in the host's immune system.² It is an important mediator of local inflammation that appears to be vital in keeping infections localized. The release of TNF- results in local activation of vascular endothelium, release of nitric oxide with vasodilatation, and increased vascular . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Lequerre, T., Jouen, F., Brazier, M., Clayssens, S., Klemmer, N., Menard, J.-F., Mejjad, O., Daragon, A., Tron, F., Le Loet, X., Vittecoq, O. (2007). Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxford) 46: 446-453 [Abstract] [Full Text]  
• Kramer, J. M., Yi, L., Shen, F., Maitra, A., Jiao, X., Jin, T., Gaffen, S. L. (2006). Cutting Edge: Evidence for Ligand-Independent Multimerization of the IL-17 Receptor. J. Immunol. 176: 711-715 [Abstract] [Full Text]  
• Ruddy, M. J., Shen, F., Smith, J. B., Sharma, A., Gaffen, S. L. (2004). Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment. J. Leukoc. Biol. 76: 135-144 [Abstract] [Full Text]  
• Alten, R, Gromnica-Ihle, E, Pohl, C, Emmerich, J, Steffgen, J, Roscher, R, Sigmund, R, Schmolke, B, Steinmann, G (2004). Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis. Ann Rheum Dis 63: 170-176 [Abstract] [Full Text]  
• Ruddy, M. J., Wong, G. C., Liu, X. K., Yamamoto, H., Kasayama, S., Kirkwood, K. L., Gaffen, S. L. (2004). Functional Cooperation between Interleukin-17 and Tumor Necrosis Factor-{alpha} Is Mediated by CCAAT/Enhancer-binding Protein Family Members. J. Biol. Chem. 279: 2559-2567 [Abstract] [Full Text]  
• Barber, J, Sheeran, T, Mulherin, D (2003). Anti-tumour necrosis factor treatment in a patient with anorexia nervosa and juvenile idiopathic arthritis. Ann Rheum Dis 62: 490-491 [Full Text]  
• Lindemann, M. J., Benczik, M., Gaffen, S. L. (2003). Anti-apoptotic Signaling by the Interleukin-2 Receptor Reveals a Function for Cytoplasmic Tyrosine Residues within the Common gamma (gamma c) Receptor Subunit. J. Biol. Chem. 278: 10239-10249 [Abstract] [Full Text]  
• Agusti, A.G.N., Noguera, A., Sauleda, J., Sala, E., Pons, J., Busquets, X. (2003). Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 21: 347-360 [Abstract] [Full Text]  
• Thomas, P., Walchner, M., Ghoreschi, K., Rocken, M. (2003). Successful Treatment of Granulomatous Cheilitis With Thalidomide. Arch Dermatol 139: 136-138 [Full Text]  
• Terslev, L, Torp-Pedersen, S, Qvistgaard, E, Kristoffersen, H, Rogind, H, Danneskiold-Samsoe, B, Bliddal, H (2003). Effects of treatment with etanercept (Enbrel, TNRF:Fc) on rheumatoid arthritis evaluated by Doppler ultrasonography. Ann Rheum Dis 62: 178-181 [Abstract] [Full Text]  
• D'Acquisto, F., May, M. J., Ghosh, S. (2002). Inhibition of Nuclear Factor Kappa B (NF-B):: An Emerging Theme in Anti-Inflammatory Therapies. Mol. Interv. 2: 22-35 [Abstract] [Full Text]  
• (2001). {blacktriangledown}Etanercept and {blacktriangledown}infliximab for rheumatoid arthritis. DTB 39: 49-52 [Abstract] [Full Text]  
• Pryhuber, G. S., O'Brien, D. P., Baggs, R., Phipps, R., Huyck, H., Sanz, I., Nahm, M. H. (2000). Ablation of tumor necrosis factor receptor type I (p55) alters oxygen-induced lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 278: L1082-L1090 [Abstract] [Full Text]  
• Sack, M. N., Smith, R. M., Opie, L. H. (2000). Tumor necrosis factor in myocardial hypertrophy and ischaemia -- an anti-apoptotic perspective. Cardiovasc Res 45: 688-695 [Full Text]  
• Goldring, S. R. (2000). A 55-Year-Old Woman With Rheumatoid Arthritis. JAMA 283: 524-531 [Full Text]  
• Cook, D. A., Dimick, J. B., Gallagher, D. C., Escalante, A., del Rincon, I., Ferraccioli, G.F., Di Poi, E., Weinblatt, M. E., Burge, D. J. (1999). Etanercept in Rheumatoid Arthritis. NEJM 340: 2000-2001 [Full Text]  
• Senter, P. D., Al-Abed, Y., Metz, C. N., Benigni, F., Mitchell, R. A., Chesney, J., Han, J., Gartner, C. G., Nelson, S. D., Todaro, G. J., Bucala, R. (2002). Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc. Natl. Acad. Sci. USA 99: 144-149 [Abstract] [Full Text]